Tower Research Capital LLC (Trc) Rain Therapeutics Inc. Transaction History

Tower Research Capital LLC (Trc)

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$0.84 - $1.22 $1,653 - $2,402	1,969 Added 31.02%	8,316 $9,000
Q3 2023 Nov 14, 2023	SELL	$0.82 - $1.42 $214 - $370	-261 Reduced 3.95%	6,347 $5,000
Q2 2023 Aug 14, 2023	BUY	$1.09 - $9.93 $7,202 - $65,617	6,608 New	6,608 $7,000
Q4 2022 Feb 10, 2023	SELL	$5.52 - $8.48 $14,109 - $21,674	-2,556 Reduced 64.48%	1,408 $11,000
Q3 2022 Nov 10, 2022	BUY	$4.75 - $8.01 $13,855 - $23,365	2,917 Added 278.61%	3,964 $19,000

Q2 2022 Aug 15, 2022	SELL	$2.21 - $5.56 $2,170 - $5,459	-982 Reduced 48.4%	1,047 $6,000
Q1 2022 May 12, 2022	BUY	$5.07 - $13.68 $5,627 - $15,184	1,110 Added 120.78%	2,029 $10,000
Q4 2021 Feb 14, 2022	SELL	$11.91 - $17.0 $678 - $969	-57 Reduced 5.84%	919 $11,000
Q3 2021 Nov 15, 2021	BUY	$13.21 - $20.91 $343 - $543	26 Added 2.74%	976 $15,000
Q2 2021 Aug 16, 2021	BUY	$15.08 - $20.3 $14,326 - $19,285	950 New	950 $15,000

122K

Ticker RAIN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 18,837,400
Description
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in...

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.